Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform

5 Jun 2025

Abstract excerpt

Over the past five years, allogeneic off-the-shelf CAR-engineered cell therapies have advanced rapidly. By bypassing the individualized manufacturing, high cost, and eligibility constraints of autologous products, allogeneic platforms, especially those derived from induced pluripotent stem cells (iPSCs), promise broader, faster access for cancer patients. This perspective reviews recent preclinical and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40480218
DOI: 10.1016/j.stemcr.2025.102515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platformPMID 40480218Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Advancing cell-based cancer immunotherapy through stem cell engineeringSemantic proximity Read ↗

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospectsSemantic proximity Read ↗

A Serum- and Feeder-Free System to Generate CD4 and Regulatory T Cells from Human iPSCsSemantic proximity Read ↗

iPS cell therapy 2.0: Preparing for next‐generation regenerative medicineSemantic proximity Read ↗

A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCsSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapySemantic proximity Read ↗

A differentiated and durable allogeneic strategy applicable to cell therapiesSemantic proximity Read ↗

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Semantic proximity Read ↗

Multiplexed iPSC platform for advanced NK cell immunotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.